Literature DB >> 15243687

Length of stay and antipsychotic treatment costs of patients with acute psychosis admitted to hospital in Spain. Description and associated factors. The Psychosp study.

Salvador Peiró1, Gregorio Gómez, Montserrat Navarro, Iris Guadarrama, Javier Rejas.   

Abstract

OBJECTIVE: The aim of this study was to describe the length of stay, cost of drug treatment, diagnostic tests and other therapeutic measures in acute psychotic patients admitted to acute in-patient psychiatric units and to analyse the factors associated with these.
METHODS: A retrospective review was made of medical records of 200 patients admitted for acute psychosis in eight Spanish hospitals. Information was collected concerning the length of stay, cost of drug treatment and diagnostic tests; bivariate and multivariate analysis was made of factors associated with length of stay and cost of antipsychotic drug treatment.
RESULTS: The average admission cost ranged between 2,830.29 and 3,624.95 euros, with a wide variability among hospitals. Of this cost, 94.3% corresponded to fixed costs, 3.4% to diagnostic tests and 2.4% to drug treatment (84.2% of this latter cost corresponded to antipsychotic drugs). Age younger than 25 years and a diagnosis of schizophrenia were associated with longer hospital stays; longer length of stay, the presence of aggressiveness/agitation, a diagnosis of schizophrenia, age younger than 25 years and the use of atypical antipsychotics were associated with higher costs in antipsychotic drug treatment.
CONCLUSIONS: The hospital admission cost of an acute psychotic episode is mostly dependent on the structural costs derived from in-patient treatment. The differences in costs seem to be related to the different length of stay schemes used by the various hospitals rather than to the clinical characteristics of patients or the drugs used.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15243687     DOI: 10.1007/s00127-004-0776-y

Source DB:  PubMed          Journal:  Soc Psychiatry Psychiatr Epidemiol        ISSN: 0933-7954            Impact factor:   4.328


  10 in total

1.  Characteristics and Needs of Psychiatric Patients With Prolonged Hospital Stay.

Authors:  Marc Afilalo; Nathalie Soucy; Xiaoqing Xue; Antoinette Colacone; Emmanuelle Jourdenais; Jean-François Boivin
Journal:  Can J Psychiatry       Date:  2015-04       Impact factor: 4.356

Review 2.  The Cost of Relapse in Schizophrenia.

Authors:  Mark Pennington; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2017-09       Impact factor: 4.981

3.  The cost of generalized anxiety disorder in primary care settings: results of the ANCORA study.

Authors:  Joan Rovira; Guillermina Albarracin; Luis Salvador; Javier Rejas; Eduardo Sánchez-Iriso; Juan M Cabasés
Journal:  Community Ment Health J       Date:  2012-04-08

4.  Cost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain.

Authors:  Miguel Bernardo; Jose Ramón Azanza; Carlos Rubio-Terrés; Javier Rejas
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

5.  Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial.

Authors:  Fernando Cañas; Víctor Pérez-Solá; Silvia Díaz; Javier Rejas
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

6.  Determinants of hospital length of stay for people with serious mental illness in England and implications for payment systems: a regression analysis.

Authors:  Rowena Jacobs; Nils Gutacker; Anne Mason; Maria Goddard; Hugh Gravelle; Tony Kendrick; Simon Gilbody
Journal:  BMC Health Serv Res       Date:  2015-09-30       Impact factor: 2.655

7.  Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.

Authors:  Tatiana Dilla; Jörgen Möller; Paul O'Donohoe; María Álvarez; José A Sacristán; Michael Happich; Antje Tockhorn
Journal:  BMC Psychiatry       Date:  2014-12-02       Impact factor: 3.630

Review 8.  Health service use and costs associated with aggressiveness or agitation and containment in adult psychiatric care: a systematic review of the evidence.

Authors:  Maria Rubio-Valera; Juan V Luciano; José Miguel Ortiz; Luis Salvador-Carulla; Alfredo Gracia; Antoni Serrano-Blanco
Journal:  BMC Psychiatry       Date:  2015-03-04       Impact factor: 3.630

9.  Care coordination for severe mental health disorders: an analysis of healthcare provider patient-sharing networks and their association with quality of care in a French region.

Authors:  Coralie Gandré; Laurent Beauguitte; Alexandre Lolivier; Magali Coldefy
Journal:  BMC Health Serv Res       Date:  2020-06-17       Impact factor: 2.655

10.  Cost of Relapse Management in Patients with Schizophrenia in Italy and Spain: Comparison Between Lurasidone and Quetiapine XR.

Authors:  Umberto Restelli; Manuel García-Goñi; Michal Lew-Starowicz; Pawel Mierzejewski; Sofia Silvola; Jacqueline Mayoral-van Son; Davide Croce; Paola Rocca; Benedicto Crespo-Facorro
Journal:  Clin Drug Investig       Date:  2020-09       Impact factor: 2.859

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.